UBS raised the firm’s price target on West Pharmaceutical (WST) to $320 from $285 and keeps a Buy rating on the shares. Growth is getting back on track for West Pharmaceutical, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services Reports Strong Q2 2025 Results
- West Pharmaceutical Services’ Earnings Call Highlights Strong Growth
- West Pharmaceutical rises 22.2%
- West Pharmaceutical price target raised to $350 from $275 at Evercore ISI
- Strong Growth Prospects and Margin Recovery Justify Buy Rating for West Pharmaceutical Services